Evidence map›Paper›PMID 40256478›Full record

ArticleGland surgery2025

Nomograms for predicting cervical central lymph node metastases and high-volume cervical central lymph node metastases in papillary thyroid carcinoma.

Xindong Huang, Xiaoxiong Gan, Jianhua Feng, Wensong Cai, Bo Xu

Abstract read
In one paragraph

Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Clinicopathological predictors of central lymph node metastasis in clinically node-negative papillary thyroid carcinoma: a retrospective cohort analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xindong HuangDepartment of Thyroid Surgery, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Xiaoxiong GanDepartment of Thyroid Surgery, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Jianhua FengDepartment of Thyroid Surgery, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Wensong CaiDepartment of Thyroid Surgery, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.
Bo XuDepartment of Thyroid Surgery, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou, China.ORCID https://orcid.org/0000-0001-6384-6685

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cervical central lymph node metastasis (CLNM) is a known risk factor for recurrent thyroid cancer (TC), and cervical high-volume central lymph node metastases (HVCLNM) are associated with higher recurrence rates and shorter disease-specific survival. The status of CLNM is critical in determining surgical strategies for papillary thyroid carcinoma (PTC). We developed two separate nomograms to predict the probability of CLNM and HVCLNM. Methods: We retrospectively analyzed 590 PTC patients who underwent total thyroidectomy or lobectomy with central lymph node dissection (CLND) between January 2020 and May 2023. Univariate and multivariate analyses were conducted to identify risk factors associated with CLNM and HVCLNM. The nomograms were internally validated using bootstrapping and evaluated on a temporal validation cohort. Results: Between January 2020 and May 2023, 1,019 patients were screened, 590 (57.9%) were eligible, and they were divided into development (n=353) and validation (n=237) cohorts. HVCLNM was present in 41 patients (11.6%). The variables with the strongest predictive value for CLNM were younger age (P<0.001), male sex (P=0.045), tumor size (P<0.001), and tumor multifocality (P=0.001). The strongest predictors for HVCLNM were younger age (P=0.001), tumor size (P<0.001), bilateral lesions (P=0.005), and preoperative serum thyroid peroxidase antibody (TPOAb) ≤14.95 IU/mL (P=0.01). The area under the curve (AUC) for the CLNM model was 0.75, with similar results achieved in internal validation (0.74) and external validation (0.68). The AUC for the HVCLNM model was 0.80, with similar values in internal validation (0.79) and external validation (0.79). Both models demonstrated good calibration, with predictions closely aligning with observed outcomes. Conclusions: Based on the quantified risk stratification offered by our nomograms, clinicians can engage in comprehensive preoperative discussions with PTC patients. Prophylactic CLND and strict postoperative evaluation may be recommended for patients with high nomogram scores.

Indexed as

cervical high-volume central lymph node metastases (cervical HVCLNM)nomogramPapillary thyroid carcinoma (PTC)thyroid peroxidase antibody (TPOAb)

Identifiers

PMID40256478
PMCPMC12004298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.